Every month ECDC provides detailed epidemiological overview of the worldwide transmission of chikungunya in its weekly threat report (Communicable Diseases Threat Report).
The food-borne infections listeriosis and shigatoxigenic Escherichia coli are increasing in the EU/EEA and were in 2022 at levels higher than before the COVID-19 pandemic.
The mosquito species Aedes albopictus, a known vector of chikungunya and dengue viruses, is establishing itself further northwards and westwards in Europe, according to the latest data.
At the start of European Immunization Week, the ECDC report “Poliomyelitis situation update” reveals that between 2012 and 2021, approximately 2.4 million children in the EU/EEA may have not received three doses of polio-containing vaccines on time. Additionally, the newly published ECDC “Measles Annual Epidemiological Report 2022” highlights the risks when having pockets of an under-vaccinated population or groups not immunised at all.
Since late February 2023 and up until 30 March 2023, 87 cases of botulism linked to intragastric injection of the botulinum neurotoxin (BoNT) have been reported.
Since late February 2023 and as of 10 March 2023, 67 cases of botulism linked to intragastric injection of the botulism neurotoxin (BoNT) have been reported in Germany (12), Austria (1), Switzerland (1) and Türkiye (53).
Immediate health needs following earthquakes in Türkiye and Syria are mostly related to trauma and the disruption of healthcare, however, infectious disease threats may be concerning in the following two to four weeks.
Hepatitis A cases in 2021 were at their lowest levels since EU-level hepatitis A surveillance began in 2007, while five other food and waterborne diseases are rising towards pre-pandemic levels. The information is revealed in the Annual Epidemiological Report 2021, of which six chapters are published today by ECDC.
Globally, as of 9 August, 19 cases of polio due to wild poliovirus type 1 (WPV1) and 223 cases due to circulating vaccine derived poliovirus (cVDPV) have been reported this year. In 2022, the cVDPV cases have been reported in 15 countries, with 93% of the cases attributed to cVDPV type 2 (cVDPV2).